JNJ Stock Has Serious Dividend Growth Ahead of It in 2018

Johnson & Johnson (NYSE:JNJ) is not only a Dividend Aristocrat, it is also a Dividend King. The 51 Dividend Aristocrats are a group of companies in the S&P 500 Index, with 25+ consecutive years of dividend increases. The Dividend Kings are an even more exclusive group of stocks, with 50+ years of consecutive dividend increases. J&J stock is one of only 22 Dividend Kings. Johnson & Johnson has been in operation for 130 years, and has raised its dividend for 55 years in a row

J&J’s pharmaceutical segment is its strongest area of growth. This segment has generated much higher growth rates than medical devices or consumer products, in recent periods. For example, J&J had adjusted earnings-per-share of $6.73 in 2016, which represented 8% growth from the previous year. Organic revenue increased 7% for 2016. By 2021, J&J expects to file 10 new products, each with annual sales potential of $1 billion or more. It also sees the potential for 40 line extensions to existing products by then. Of these 40 extensions, 10 of which have the potential for more than $500 million in annual revenue.

Source: InvestorPlace

Related Articles:
- 4 Dividend Stocks Delivering The Secret To Successful Investing
- The Magnificent Marvelous Money Machine
- 5 Five-Star Dividend Stocks
- My Top 3 Investing Mistakes
- 6 Stocks Currently Trading Below their Fair Value